Xarelto® Indications
Stroke prevention in NVAF
Xarelto is indicated for stroke and systemic embolism prevention in adults with non-valvular atrial fibrillation with one or more risk factors. Risk factors include congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack
Treatment of PE/DVT and prevention of recurrent VTE
Xarelto is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults
Prevention of atherothrombotic events in chronic CAD patients at high risk of ischaemic events
Xarelto (rivaroxaban) 2.5 mg BID, co-administered with aspirin, is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) at high risk of ischaemic events
Prevention of atherothrombotic events in symptomatic PAD patients at high risk of ischaemic events
Xarelto, co-administered with aspirin, is indicated for the prevention of atherothrombotic events in adult patients with symptomatic peripheral artery disease (PAD) at high risk of ischaemic events
Secondary prevention in ACS
Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers
Prevention of VTE after elective hip replacement surgery
The first approved indication for Xarelto was for the prevention of venous thromboembolism in adults undergoing elective hip replacement surgery
Prevention of VTE after elective knee replacement surgery
The first approved indication for Xarelto was for the prevention of venous thromboembolism in adults undergoing elective knee replacement surgery
Based on results from the EINSTEIN Junior trial in children aged 0-17, you can now offer an oral anticoagulation treatment,*,§
Xarelto® is indicated for the treatment of VTE and the prevention of VTE in neonates, infants and toddlers, children and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation.
Footnotes
* Not recommended in patients with CrCl <15 ml/min and in patients with renal impairment when concomitantly receiving medicinal products that increase rivaroxaban plasma concentration.
Not recommended in children 1 year or older with moderate or severe renal impairment (glomerular filtration rate < 50 mL/min/1.73 m^2), as no clinical data is available.
Not recommended in children younger than 1 year with serum creatinine results above 97.5th percentile, as no clinical data are available.
§ After at least 5 days of parenteral anticoagulation treatment.
Volume and frequency of administration of Xarelto is dependent on a child’s weight and will need to be adjusted if the child receives Xarelto for a long period of time.
NVAF, non-valvular atrial fibrillation; PE, pulmonary embolism; DVT, deep vein thrombosis; CAD, coronary artery disease; BID, twice daily; PAD, peripheral artery disease; ACS, acute coronary syndrome; THR, total hip replacement; TKR, total knee replacement; VTE, venous thromboembolism.
PP-XAR-GB-3588 | February 2024
- expand_more